Evaluation of cell-penetrating peptide-peptide nucleic acid effect in the inhibition of cagA in Helicobacter pylori.
Antigens, Bacterial
/ genetics
Bacterial Load
/ drug effects
Bacterial Proteins
/ antagonists & inhibitors
Cell Line, Tumor
HT29 Cells
Helicobacter Infections
/ drug therapy
Helicobacter pylori
/ drug effects
Humans
Microbial Sensitivity Tests
Oligodeoxyribonucleotides, Antisense
/ genetics
Peptide Nucleic Acids
/ genetics
Real-Time Polymerase Chain Reaction
Helicobacter pylori
antisense
cell culture
peptide nucleic acid
real-time PCR
Journal
Acta microbiologica et immunologica Hungarica
ISSN: 1588-2640
Titre abrégé: Acta Microbiol Immunol Hung
Pays: Hungary
ID NLM: 9434021
Informations de publication
Date de publication:
11 Feb 2020
11 Feb 2020
Historique:
received:
30
11
2018
accepted:
15
05
2019
pubmed:
12
2
2020
medline:
23
6
2021
entrez:
12
2
2020
Statut:
epublish
Résumé
Helicobacter pylori is the most common cause of chronic infection in human and is associated with gastritis, peptic ulcer disease, and adenocarcinoma of mucosa-associated lymphoid tissue cells. Peptide nucleic acid (PNA) is a synthetic compound, which can inhibit the production of a particular gene. This study aimed to investigate the effect of PNA on inhibiting the expression of cagA. After confirmation of the desired gene by polymerase chain reaction (PCR), the antisense sequence was designed against cagA gene. The minimum inhibitory concentrations of conjugated PNA against H. pylori was determined. The effect of the compound on the expression level of the cagA was investigated in HT29 cell culture using real-time PCR. The results showed 2 and 3 log reduction in bacterial count after 8- and 24-h treatment with 4 and 8 μM of the compound, respectively. The lowest expression level of the cagA gene was observed at a concentration of 8 μM after 6 h. The results of this study showed that cell-penetrating peptide antisense can be employed as effective tools for inhibiting the target gene mRNA for various purposes. Moreover, further research is necessary to assess the potency, safety, and pharmacokinetics of CPP-PNAs for clinical prevention and treatment of infections due to H. pylori.
Identifiants
pubmed: 32043369
doi: 10.1556/030.66.2019.032
doi:
Substances chimiques
Antigens, Bacterial
0
Bacterial Proteins
0
Oligodeoxyribonucleotides, Antisense
0
Peptide Nucleic Acids
0
cagA protein, Helicobacter pylori
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM